Evaluation of Label Drug in the Treatment Polycystic Ovary Syndrome

DOI

10.2991/ahsr.k.200523.032How to use a DOI?

Keywords

off label, ovary, polycystic, syndrome

Abstract

Objectives: Polycystic ovary syndrome (PCOS) is defined as high levels of hyperandrogenism, menstrual irregularities, anovulation and high levels of insulin (hyperinsulinemia secondary to increased insulin resistance).The estimated that> 75% of women with PCOS are insulin resistant, the incidence of PCOS affects 4% -8% of reproductive-aged women. The aims of this study to an evaluation of metformin treatment of PCOS. This research was a cross-sectional study with prospective data collection conducted From January to May 2019. Data from 16 participants were involved in this study, with the criteria inclusion. Data were processed statistically using Paired Sample T-test analysis to determine the effectiveness and side effects of metformin. There was a significant difference between the thickening of the endometrium before and after metformin treatment (P 0.001 <0.005). In observing the side effects, it was found that the use of metformin treatment was seen from random plasma glucose measurements on day 0, 3, 6 and 9 obtained (P 0.009<0.005) there were significant differences between the groups of random plasma glucose measurement days 0, 3, 6 and 9.

Copyright

© 2020, the Authors. Published by Atlantis Press.

Open Access

This is an open access article distributed under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)

TY  - CONF
AU  - Keni Idacahyati
AU  - Tita Nofianti
AU  - Ema Sintya Nurjaya
PY  - 2020
DA  - 2020/06/08
TI  - Evaluation of Label Drug in the Treatment Polycystic Ovary Syndrome
BT  - The proceedings of the 2nd Bakti Tunas Husada-Health Science International Conference (BTH-HSIC 2019)
PB  - Atlantis Press
SP  - 131
EP  - 134
SN  - 2468-5739
UR  - https://doi.org/10.2991/ahsr.k.200523.032
DO  - 10.2991/ahsr.k.200523.032
ID  - Idacahyati2020
ER  -